美国对进口品牌药品征收100%的关税,除非在美国制造,这威胁到澳大利亚的低成本医药计划。 U.S. to impose 100% tariffs on imported branded drugs unless made in America, threatening Australia’s low-cost medicine program.

美国建议从2025年10月1日起对进口品牌药品征收100%的关税,除非制造商建造美国生产设施,威胁澳大利亚负担得起的医药计划。 The U.S. has proposed a 100% tariff on imported branded pharmaceuticals starting October 1, 2025, unless manufacturers build U.S. production facilities, threatening Australia’s affordable medicine program. 这一转移风险会破坏澳大利亚的药品福利计划,该计划使数百万人的药品成本保持低水平,并已经引发了市场波动,一些健康库存在从某些公司获得保证后出现反弹之前急剧下降。 The move risks undermining Australia’s Pharmaceutical Benefits Scheme, which keeps drug costs low for millions, and has already triggered market volatility, with some health stocks dropping sharply before rebounding on reassurances from certain companies. 该政策反映了美国更广泛的贸易向转折和保护主义的转变,引起了对全球供应链稳定性和获得医疗保健机会的关切。 The policy reflects broader U.S. trade shifts toward reshoring and protectionism, raising concerns about global supply chain stability and healthcare access.